计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| L125046-50mg |
50mg |
现货 ![]() |
| |
| L125046-250mg |
250mg |
现货 ![]() |
| |
| L125046-1g |
1g |
现货 ![]() |
| |
| L125046-5g |
5g |
现货 ![]() |
| |
| L125046-10g |
10g |
期货 ![]() |
| |
| L125046-25g |
25g |
期货 ![]() |
| |
| L125046-100g |
100g |
现货 ![]() |
|
| 别名 | 来那度胺 | 3-(4-氨基-1,3-二氢-1-氧代-2H-异吲哚-2-基)-2,6-哌啶二酮 | 3-(4-氨基-1-异吲哚啉-2-基)哌啶-2,6-二酮 | 3-(4-氨基-1-氧代异吲哚-2-基)哌啶-2,6-二酮 | 1-氧-4-氨基-2-(2,6-二氧哌啶-3-基)异吲哚 |
|---|---|
| 英文别名 | CC-5013 | (3S)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione | 2, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)- | ENMD 0997 | Q425681 | LENALIDOMIDE [VANDF] | AB01273975-01 | 1-benzylpiperidin-4-one oxime;1-Benzyl-4-piperidinone Oxi |
| 规格或纯度 | Moligand™, ≥99% |
| 英文名称 | Lenalidomide |
| 生化机理 | 来那度胺是一种沙利度胺类似物,具有抑制 TNF-α 分泌和免疫调节的特性。具有强效抗肿瘤和抗炎作用。调节和增强宿主对多发性骨髓瘤的免疫反应。体外活性。 |
| 储存温度 | -20°C储存,充氩 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | CRL4(CRBN)E3 泛素连接酶抑制剂 |
| 备注 | 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
| 产品介绍 |
Lenalidomide (CC-5013)是Thalidomide的衍生物,是一种TNF-α分泌抑制剂,IC50为13 nM。 A Thalidomide analog known to have immunomodulatory properties Lenalidomide (CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM. |
| 纯度 | ≥99% |
| ALogP | -0.5 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504757865 |
|---|---|
| EC号 | 691-297-1 |
| 分子类型 | 小分子 |
| IIUPAC Name | 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione |
| INCHI | 1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18) |
| InChi Key | GOTYRUGSSMKFNF-UHFFFAOYSA-N |
| Smiles | C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N |
| Isomeric SMILES | C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N |
| 关联CAS | 191732-72-6 |
| NSC Number | 747972 |
| MeSH Entry Terms | 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H- isoindol-2-yl)-;3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione;CC 5013;CC-5013;CC5013;IMiD3 cpd;lenalidomide;Revimid;Revlimid |
| 分子量 | 259.27 |
| Reaxy-Rn | 8335210 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=8335210&ln= |
| 溶解性 | Soluble in DMSO (≥52 mg/ml) at 25 °C, methanol and water (2: 1), buffered aqueous solvents, water (<1 mg/ml) at 25 °C, and ethanol (<1 mg/ml) at 25 °C. |
|---|---|
| 敏感性 | 对热敏感 |
| 分子量 | 259.260 g/mol |
| XLogP3 | -0.500 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 4 |
| 可旋转键计数Rotatable Bond Count | 1 |
| 精确质量Exact Mass | 259.096 Da |
| 单同位素质量Monoisotopic Mass | 259.096 Da |
| 拓扑极表面积Topological Polar Surface Area | 92.500 Ų |
| 重原子数Heavy Atom Count | 19 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 437.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 1 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | L125046 | |
| 分析证书 | L125046 | |
| 分析证书 | L125046 | |
| 分析证书 | L125046 | |
| 分析证书 | L125046 | |
| 分析证书 | L125046 | |
| 分析证书 | L125046 | |
| 分析证书 | L125046 | |
| 分析证书 | L125046 | |
| 分析证书 | L125046 | |
| 分析证书 | L125046 |
| 1. Graubert TA, Payton MA, Shao J, Walgren RA, Monahan RS, Frater JL, Walshauser MA, Martin MG, Kasai Y, Walter MJ. (2009) Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis.. PLoS ONE, 4 (2): (e4583). [PMID:19240791] |
| 2. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL et al.. (2011) Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.. Blood, 118 (18): (4771-9). [PMID:21860026] |
| 3. Petzold G, Fischer ES, Thomä NH. (2016) Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.. Nature, 532 (7597): (127-30). [PMID:26909574] |
| 4. Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK et al.. (2015) Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.. Nature, 523 (7559): (183-188). [PMID:26131937] |
| 5. Xiaohe Li, Qing Liang, Shaoyan Gao, Qiuyan Jiang, Fangxia Zhang, Ruiqin Zhang, Hao Ruan, Shuangling Li, Jiaoyan Luan, Ruxia Deng, Honggang Zhou, Hui Huang, Cheng Yang. (2022) Lenalidomide attenuates post-inflammation pulmonary fibrosis through blocking NF-κB signaling pathway. INTERNATIONAL IMMUNOPHARMACOLOGY, 103 (108470). [PMID:34952465] [10.1016/j.intimp.2021.108470] |
| 6. Yue-Yue Chang, Hai-Long Wu, Huan Fang, Tong Wang, Yang-Zi Ouyang, Xiao-Dong Sun, Gao-Yan Tong, Yu-Jie Ding, Ru-Qin Yu. (2021) Comparison of three chemometric methods for processing HPLC-DAD data with time shifts: Simultaneous determination of ten molecular targeted anti-tumor drugs in different biological samples. TALANTA, 224 (121798). [PMID:33379025] [10.1016/j.talanta.2020.121798] |